MDGL — Madrigal Pharmaceuticals Balance Sheet
0.000.00%
- $9.78bn
- $9.10bn
- $180.13m
- 61
- 12
- 97
- 58
Annual balance sheet for Madrigal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 284 | 270 | 359 | 634 | 926 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | — | 53.8 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 285 | 272 | 361 | 637 | 1,033 |
| Net Property, Plant And Equipment | 1.83 | 1.65 | 1.2 | 3.27 | 4.59 |
| Net Intangible Assets | |||||
| Total Assets | 287 | 273 | 363 | 641 | 1,042 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 46.6 | 76.8 | 116 | 119 | 169 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 47 | 77.2 | 165 | 235 | 288 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 240 | 196 | 197 | 405 | 754 |
| Total Liabilities & Shareholders' Equity | 287 | 273 | 363 | 641 | 1,042 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |